Heart Protein Regulates Blood Vessel Maintenance
BOSTON (May 11, 2009) - In a study led by Akiko Hata, PhD, of Tufts
University School of Medicine, researchers have shown that a protein
expressed in the heart, FHL2, inhibits the genes necessary for the
quiescence of vascular smooth muscle cells (vSMCs), which line blood
vessels. Vascular smooth muscle cells undergo a process in diseases such
as atherosclerosis or normal tissue damage caused by balloon angioplasty
where they transition between a resting and proliferative state. The
ability to transition between the two states is necessary for the normal
development of blood vessels, regulating blood pressure, and repairing
vessels that suffer from injury.
"By understanding the pathways that modulate vSMCs, we are closer to
being able to develop reagents to ameliorate abnormal function of blood
vessels," says Hata, associate professor at Tufts University School of
Medicine and a member of the biochemistry program faculty at the Sackler
School of Graduate Biomedical Sciences at Tufts.
The researchers have previously shown that BMPs (Bone Morphogenetic
Proteins) play a role in the maintenance of smooth muscle cells in the
pulmonary artery. In this study, the research demonstrates that FHL2
(Four-and-a-Half LIM Domain Protein 2) inhibits activation of genes that
are involved in contraction of smooth muscle cells by at least one of
the BMPs.
"We also found that FHL2 is important in the regulation of vasomotor
tone, or the contraction and relaxation of muscles in the blood vessel.
This is important because dysfunction in vasomotor tone is thought to
cause high blood pressure. Our study demonstrates that FHL2 is essential
in modulating the physical state of vSMCs, which is essential in
regulating vascular motor function," says Hata.
First author Nicole Neuman is a graduate student in the Sackler School
of Graduate Biomedical Sciences at Tufts and is a member of the
Molecular Signaling Laboratory at the Molecular Cardiology Research Institute (MCRI) at Tufts Medical Center.
Senior author Akiko Hata, PhD, is also the director of the Molecular
Signaling Laboratory at the MCRI at Tufts Medical Center.
This study was funded by the National Heart, Lung and Blood Institute at
the National Institutes of Health.
Neuman NA, Ma S, Schnitzler GR, Zhu Y, Lagna, G, and Hata A. The Journal
of Biological Chemistry. 2009. (May 8); 284 (19): 13202-13212. "The
Four-and-a-half LIM Domain Protein 2 Regulates Vascular Smooth Muscle
Phenotype and Vascular Tone." Published online March 5, 2009, doi:
10.1074/jbc.M900282200
About Tufts University School of Medicine
Tufts University School of Medicine and the Sackler School of Graduate
Biomedical Sciences at Tufts University are international leaders in
innovative medical education and advanced research. The School of
Medicine and the Sackler School are renowned for excellence in education
in general medicine, special combined degree programs in business,
health management, public health, bioengineering and international
relations, as well as basic and clinical research at the cellular and
molecular level. Ranked among the top in the nation, the School of
Medicine is affiliated with six major teaching hospitals and more than
30 health care facilities. The Sackler School undertakes research that
is consistently rated among the highest in the nation for its impact on
the advancement of medical science.
If you are a member of the media interested in learning more about this
topic, or speaking with a faculty member at the Tufts University School
of Medicine, the Sackler School of Graduate Biomedical Sciences, or
another Tufts health sciences researcher, please contact Siobhan
Gallagher at 617-636-6586.